###begin article-title 0
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 33 44 33 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
parkin counteracts symptoms in a Drosophila model of Parkinson's disease
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 312 322 308 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
###xml 326 333 322 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 463 473 455 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
###xml 476 487 468 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 451 456 <span type="species:ncbi:9606">human</span>
Parkinson's disease, a prevalent neurodegenerative disease, is characterized by the reduction of dopaminergic neurons resulting in the loss of motor control, resting tremor, the formation of neuronal inclusions and ultimately premature death. Two inherited forms of PD have been linked to mutations in the alpha-synuclein and parkin genes. The parkin protein functions as an ubiquitin ligase targeting specific proteins for degradation. Expression of human alpha-synuclein in Drosophila neurons recapitulates the loss of motor control, the development of neuronal inclusions, degeneration of dopaminergic neurons and the ommatidial array to provide an excellent genetic model of PD.
###end p 2
###begin title 3
Results
###end title 3
###begin p 4
###xml 27 33 27 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin</italic>
###xml 64 75 64 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 102 109 102 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 174 181 174 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 222 229 222 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 240 250 236 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
###xml 299 308 291 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein</italic>
###xml 388 395 380 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 428 437 416 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein</italic>
###xml 569 578 553 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein</italic>
###xml 589 600 573 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 134 139 <span type="species:ncbi:4932">yeast</span>
To investigate the role of parkin, we have generated transgenic Drosophila that conditionally express parkin under the control of the yeast UAS enhancer. While expression of parkin has little consequence, co-expression of parkin with alpha-synuclein in the dopaminergic neurons suppresses the alpha-synuclein-induced premature loss of climbing ability. In addition directed expression of parkin in the eye counteracts the alpha-synuclein-induced degeneration of the ommatidial array. These results show that parkin suppresses the PD-like symptoms observed in the alpha-synuclein-dependent Drosophila model of PD.
###end p 4
###begin title 5
Conclusion
###end title 5
###begin p 6
###xml 21 28 21 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 289 296 281 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 85 90 <span type="species:ncbi:9606">human</span>
###xml 245 251 <span type="species:ncbi:9606">humans</span>
The highly conserved parkin E3 ubiquitin ligase can suppress the damaging effects of human alpha-synuclein. These results are consistent with a role for parkin in targeting alpha-synuclein to the proteasome. If this relationship is conserved in humans, this suggests that up-regulation of parkin should suppress alpha-synucleinopathic PD. The development of therapies that regulate parkin activity may be crucial in the treatment of PD.
###end p 6
###begin title 7
Background
###end title 7
###begin p 8
###xml 267 268 267 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 269 270 269 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 651 652 651 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 773 774 773 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 775 776 775 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 641 649 <span type="species:ncbi:9606">patients</span>
Parkinson's disease (PD) is a neurodegenerative disorder that is characterized by muscle tremors in stationary limbs, bradykinesia (slowed movement) and difficulty initiating and sustaining movements, and affects 1-2% of the population older than sixty years of age [1-5]. As the disease progresses, both the sense of balance and the memory of the affected individual deteriorate. Post-mortem analysis reveals the selective loss of dopaminergic neurons from the substantia nigra region of the brain. Filamentous protein inclusions, known as Lewy bodies, are found within the neuronal cell bodies of the affected area, in most but not all PD patients [4]. Although the majority of PD cases appear to be sporadic, about 5-15% have been determined to have an inherited basis [6,7]. Recently, mutations in a number of genes have been identified as causes of PD and many of these genes are associated with the ubiquitin/proteasome protein degradation pathway.
###end p 8
###begin p 9
###xml 116 117 112 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 118 119 114 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 244 246 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 247 249 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 324 326 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 327 329 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 355 365 339 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
###xml 371 372 355 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 373 374 357 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 466 468 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 469 471 449 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
Mutations in the gene encoding the alpha-synuclein protein lead to the development of Autosomal Dominant PD (ADPD) [8,9]. The alpha-synuclein protein is an abundant 140 amino acid, cytosolic protein found at the pre-synaptic region of neurons [10,11]. alpha-synuclein appears to be involved in the biosynthesis of dopamine [12,13]. Mutations in the alpha-synuclein gene [8,9] may lead to enhanced oligomerization and fibril formation of the alpha-synuclein protein [14-16].
###end p 9
###begin p 10
###xml 159 166 159 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 311 313 311 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 314 316 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 334 341 334 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 380 382 380 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 511 513 511 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 752 754 752 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 755 757 755 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 910 912 906 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 934 936 930 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 949 951 945 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1003 1005 995 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1027 1029 1019 1021 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1030 1032 1022 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1047 1054 1039 1046 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 322 328 <span type="species:ncbi:9606">humans</span>
Autosomal Recessive Juvenile Parkinson's disease (ARJP), another inherited form of PD, has been attributed to a number of point mutations and deletions of the parkin gene [17-19]. ARJP is specifically characterized by a very early age of onset, mostly before forty years of age, and the absence of Lewy bodies [20-22]. In humans, the parkin gene encodes a 465 amino acid protein [17] that functions as one of a number of E3 ubiquitin protein ligases, components of the ubiquitin/proteasome degradation pathway [23]. Ubiquitin protein ligases act to identify damaged, misfolded, and short-lived proteins to mediate the ubiquitination (the sequential attachment of a number of ubiquitin monomers) of these proteins, which are targeted to the proteasome [24,25]. Experiments in tissue culture have demonstrated that parkin can ubiquitinate a number of substrates including a glycosylated form of alpha-synuclein [26], the Pael receptor [27], CDCrel-1 [28], the alpha-synuclein-binding protein synphilin-1 [29], and parkin itself [28,30]. The loss of parkin may lead to an accumulation of one or a number of proteins in sufficient quantities to cause neuronal cell death.
###end p 10
###begin p 11
###xml 140 147 136 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 228 238 220 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
###xml 239 241 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 242 244 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 533 535 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
The interaction of parkin with alpha-synuclein suggests a common mechanism underlying inherited forms of PD. Indeed, elevated expression of parkin protects neuronal explants from the toxicity associated with expression of alpha-synuclein [26,31]. The disease inducing-forms of alpha-synuclein may prevent its degradation and result in toxic accumulation. In ARJP, functional parkin protein is lost along with the ability to mediate the ubiquitination of glycosylated alpha-synuclein and may lead to the accumulation of this protein [26]. Our working hypothesis is that aspects of parkin-mediated protein degradation are compromised in PD.
###end p 11
###begin p 12
###xml 10 34 10 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila melanogaster </italic>
###xml 105 114 101 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein</italic>
###xml 129 140 125 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 141 143 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 171 180 163 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein</italic>
###xml 363 372 351 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein</italic>
###xml 581 591 565 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
###xml 767 769 751 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 10 33 <span type="species:ncbi:7227">Drosophila melanogaster</span>
###xml 93 98 <span type="species:ncbi:9606">human</span>
The first Drosophila melanogaster model of PD was generated by the conditional expression of human alpha-synuclein in transgenic Drosophila [32]. Flies that express alpha-synuclein, in either a pan-neural or dopaminergic neuron specific manner, show a marked age-dependent loss of dorsal-medial dopaminergic neurons. Cytoplasmic inclusions were observed in alpha-synuclein-expressing flies approximately 20 days after eclosion. While control flies exhibit a strong negative geotaxis, these transgenic flies prematurely lose their climbing ability. In addition, expression of alpha-synuclein in the developing eye results in precocious degeneration of the retina. In this model expression of a number of genes are dysregulated prior to the onset of neurodegeneration [33]. These features recapitulate the main behavioural and pathological phenotypes of PD and provide an excellent model system to study the biological basis of the disease.
###end p 12
###begin p 13
###xml 4 15 4 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 21 31 17 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
###xml 339 341 335 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 385 391 381 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HSP70 </italic>
###xml 407 417 399 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
###xml 463 465 455 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 773 775 761 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 812 819 800 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 896 906 880 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
###xml 909 920 893 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 921 923 905 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 806 811 <span type="species:ncbi:9606">human</span>
The Drosophila alpha-synuclein based model has been used to investigate a number of aspects of PD. Pharmacological agents, such as the dopamine precursor levodopa, dopamine receptor agonists (bromocriptine, pergolide and SK&F38393), and the anticholinergic atropine, were demonstrated to modify the age-dependent loss of climbing ability [34]. Co-expression of the molecular chaperone HSP70 gene with alpha-synuclein prevented dopaminergic neuronal degeneration [35]. Interference with endogenous chaperone activity accelerated the toxicity of alpha-synuclein demonstrating a role for chaperones in the pathology of the disease. Suppression of HSP90, a negative regulator of the heat shock factor 1, by feeding flies geldanamycin prevents dopaminergic neuronal cell death [36]. Recently, the expression of human parkin has been shown to suppress the loss of dopaminergic neurons induced by alpha-synuclein in Drosophila [37]. This model has proven to be an effective tool in the investigation of the biological basis of PD.
###end p 13
###begin p 14
###xml 27 34 27 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 47 56 43 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein</italic>
###xml 95 105 91 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
###xml 147 158 143 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 171 178 167 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 222 229 218 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 265 275 257 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
To investigate the role of parkin in the alpha-synuclein-based model of Parkinson's disease in Drosophila, we have characterized and expressed the Drosophila homologue of parkin in this model. Our results demonstrate that parkin can counteract the effects of alpha-synuclein on climbing activity and retinal degeneration.
###end p 14
###begin title 15
Results
###end title 15
###begin title 16
###xml 20 50 20 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila melanogaster parkin</italic>
###xml 20 43 <span type="species:ncbi:7227">Drosophila melanogaster</span>
Characterization of Drosophila melanogaster parkin
###end title 16
###begin p 17
###xml 4 35 4 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila melanogaster parkin </italic>
###xml 170 177 170 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 372 374 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 415 422 415 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 487 494 487 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 747 758 747 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 827 829 827 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 973 975 973 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 999 1017 999 1017 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila parkin </italic>
###xml 1061 1063 1061 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 4 27 <span type="species:ncbi:7227">Drosophila melanogaster</span>
The Drosophila melanogaster parkin homologue was identified through a search of the Berkeley Drosophila Genome Project (BDGP) utilizing the tBlastn search algorithm. The parkin gene is located on the left arm of the third chromosome, in the polytene chromosome section 78C within the genomic scaffolding region AE003593 (BDGP), and consists of 6 exons over 2.2 kb (Figure 1A). A search of the genome for additional parkin homologues revealed none. Our analysis confirmed the sequence of parkin to be identical to that reported by the BDGP (AY058754.1). Two potential initiation codons for the parkin protein are separated by 42 base pairs at the 5' region of the transcript. As the second potential start codon is preceded by CAAA, a match to the Drosophila Kozak consensus sequence (C/A)AA(A/C)ATG) of translation initiation [38], we have assigned this as the most likely start codon. Furthermore, of the preceding fourteen potential codons only two use preferred codons [39] (data not shown). The Drosophila parkin gene was reported by Greene and colleagues [40], while the current experiments were being conducted.
###end p 17
###begin title 18
The parkin protein is well conserved
###end title 18
###begin p 19
###xml 4 28 4 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila melanogaster </italic>
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 162 180 162 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rattus norvegicus </italic>
###xml 198 211 198 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mus musculus </italic>
###xml 320 334 320 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R. norvegicus </italic>
###xml 338 350 338 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M. musculus </italic>
###xml 415 431 415 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D. melanogaster </italic>
###xml 484 486 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 530 548 530 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Anopheles gambiae </italic>
###xml 569 571 569 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 591 597 591 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin</italic>
###xml 604 619 604 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D. melanogaster</italic>
###xml 625 636 625 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A. gambiae </italic>
###xml 903 914 903 914 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A. gambiae </italic>
###xml 968 984 968 984 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D. melanogaster </italic>
###xml 999 1001 999 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 4 27 <span type="species:ncbi:7227">Drosophila melanogaster</span>
###xml 84 89 <span type="species:ncbi:9606">human</span>
###xml 162 179 <span type="species:ncbi:10116">Rattus norvegicus</span>
###xml 198 210 <span type="species:ncbi:10090">Mus musculus</span>
###xml 320 333 <span type="species:ncbi:10116">R. norvegicus</span>
###xml 338 349 <span type="species:ncbi:10090">M. musculus</span>
###xml 415 430 <span type="species:ncbi:7227">D. melanogaster</span>
###xml 530 547 <span type="species:ncbi:7165">Anopheles gambiae</span>
###xml 604 619 <span type="species:ncbi:7227">D. melanogaster</span>
###xml 625 635 <span type="species:ncbi:7165">A. gambiae</span>
###xml 903 913 <span type="species:ncbi:7165">A. gambiae</span>
###xml 968 983 <span type="species:ncbi:7227">D. melanogaster</span>
The Drosophila melanogaster parkin protein has been reported to be 42% identical to human parkin [40] (Figure 1B). Parkin protein homologues were identified from Rattus norvegicus (NM_020093.1) and Mus musculus (AB019558.1) via the tblastn algorithm of the National Center for Biotechnology Information (NCBI). Both the R. norvegicus and M. musculus homologues were found to have 44% identity and 60% similarity to D. melanogaster parkin when analysed by the blast2 algorithm (Figure 1B). In addition, we have determined that the Anopheles gambiae sequence XM316606.1 [41] is a homologue of parkin. Like D. melanogaster, the A. gambiae transcript has two potential in-frame translation start sites. The Kozak sequence prior to the first ATG is very poor, however the second site closely resembles the consensus sequence and therefore it is very likely the start site. We determined that the theoretical A. gambiae parkin protein has 65% identity and 79% similarity to D. melanogaster parkin (Figure 1B). The parkin protein appears to be highly conserved at the amino acid sequence level.
###end p 19
###begin p 20
###xml 13 29 13 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D. melanogaster </italic>
###xml 63 73 63 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A. gambiae</italic>
###xml 75 88 75 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R. norvegicus</italic>
###xml 90 102 90 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M. musculus </italic>
###xml 106 117 106 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. sapiens </italic>
###xml 225 227 225 227 <underline xmlns:xlink="http://www.w3.org/1999/xlink">Ub</underline>
###xml 236 237 236 237 <underline xmlns:xlink="http://www.w3.org/1999/xlink">l</underline>
###xml 259 260 259 260 <underline xmlns:xlink="http://www.w3.org/1999/xlink">U</underline>
###xml 266 267 266 267 <underline xmlns:xlink="http://www.w3.org/1999/xlink">P</underline>
###xml 273 274 273 274 <underline xmlns:xlink="http://www.w3.org/1999/xlink">D</underline>
###xml 291 292 291 292 <underline xmlns:xlink="http://www.w3.org/1999/xlink">R</underline>
###xml 298 299 298 299 <underline xmlns:xlink="http://www.w3.org/1999/xlink">I</underline>
###xml 310 311 310 311 <underline xmlns:xlink="http://www.w3.org/1999/xlink">N</underline>
###xml 314 315 314 315 <underline xmlns:xlink="http://www.w3.org/1999/xlink">G</underline>
###xml 348 349 348 349 <underline xmlns:xlink="http://www.w3.org/1999/xlink">I</underline>
###xml 352 353 352 353 <underline xmlns:xlink="http://www.w3.org/1999/xlink">B</underline>
###xml 360 361 360 361 <underline xmlns:xlink="http://www.w3.org/1999/xlink">R</underline>
###xml 408 410 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 511 522 511 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A. gambiae </italic>
###xml 526 541 526 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D. melanogaster</italic>
###xml 648 650 648 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 673 684 673 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 696 698 696 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 764 775 764 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 920 922 920 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 932 934 932 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 946 962 946 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D. melanogaster </italic>
###xml 966 977 966 977 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A. gambiae </italic>
###xml 1039 1041 1039 1041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 1124 1125 1124 1125 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1129 1135 1129 1135 <sub xmlns:xlink="http://www.w3.org/1999/xlink">9...39</sub>
###xml 1139 1144 1139 1144 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1...3</sub>
###xml 1148 1153 1148 1153 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2...3</sub>
###xml 1159 1160 1159 1160 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1164 1170 1164 1170 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4...48</sub>
###xml 1174 1175 1174 1175 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1216 1218 1216 1218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 1233 1235 1233 1235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 1345 1347 1345 1347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 1361 1363 1361 1363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 1460 1462 1460 1462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1463 1465 1463 1465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1466 1468 1466 1468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 2071 2073 2071 2073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 2290 2292 2290 2292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 2326 2333 2326 2333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 2375 2393 2375 2393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila parkin </italic>
###xml 2394 2396 2394 2396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 13 28 <span type="species:ncbi:7227">D. melanogaster</span>
###xml 63 73 <span type="species:ncbi:7165">A. gambiae</span>
###xml 75 88 <span type="species:ncbi:10116">R. norvegicus</span>
###xml 90 101 <span type="species:ncbi:10090">M. musculus</span>
###xml 106 116 <span type="species:ncbi:9606">H. sapiens</span>
###xml 511 521 <span type="species:ncbi:7165">A. gambiae</span>
###xml 526 541 <span type="species:ncbi:7227">D. melanogaster</span>
###xml 585 590 <span type="species:ncbi:9606">human</span>
###xml 631 636 <span type="species:ncbi:9606">human</span>
###xml 946 961 <span type="species:ncbi:7227">D. melanogaster</span>
###xml 966 976 <span type="species:ncbi:7165">A. gambiae</span>
###xml 2312 2317 <span type="species:ncbi:10090">mouse</span>
###xml 2322 2325 <span type="species:ncbi:10116">rat</span>
Alignment of D. melanogaster parkin protein sequences with the A. gambiae, R. norvegicus, M. musculus and H. sapiens homologues reveals conservation of the protein throughout a number of characteristic domains, including the Ubiquitin- like Domain (UBL), the Unique Parkin Domain (UPD), the Really Interesting New Gene finger 1 (RING1) domain, the In- Between Ring (IBR) domain, and the RING2 domain (Figure 1B). In the amino-terminal region of the proteins, the first 15 amino acids are well conserved between A. gambiae and D. melanogaster, but absent in the mammalian proteins. The human UBL shows very high similarity (62%) to human ubiquitin [17]. Correspondingly the Drosophila UBL (Figure 1B, green box) was found to have 43% identity and 67% similarity to Drosophila ubiquitin (AAA29007; data not shown). The second highly conserved region is unique to parkin and has been termed the unique parkin domain (UPD) [42] (Figure 1B, red box). D. melanogaster and A. gambiae share a similar eight amino acid insertion in the UPD (Figure 1B). There are two RING-finger domains that are defined by the consensus sequence C-X2-C-X9...39-C-X1...3-H-X2...3-C/H-X2-C-X4...48-C-X2-C where X can be any amino acid (Figure 1B, blue boxes) [43]. These RING-finger domains flank a cysteine-rich domain designated the In-Between Ring (IBR) domain (Figure 1B, black box) [44]. These three domains are responsible for binding to specific E2 ubiquitin conjugating enzymes [23,28,30]. Between the RING1 and the IBR domains there is an eighteen amino acid stretch of high conservation with the sequence (N/H)S(L/F)I(K/E)(E/D)(I/L)HHF(K/R)(L/I)LX(R/E)E(E/Q)Y. A 41 amino acid segment separates the IBR and RING2 domains, and while the first half of this segment is not well conserved the second half is highly conserved with the sequence AX(E/Q)ARW(D/E)XA(S/T)(N/K)X(T/A)IKX(S/T)TKP. The carboxy-terminus is well conserved and has the following sequence M(G/A)XHWF(G/D)(-/V), suggesting a possible conserved function for the tail of the protein. As parkin undergoes self-ubiquitination [28], conserved potential ubiquitination sites (lysine residues) were identified. There is a lysine residue that is completely conserved at K-42 of the dipterans and this corresponding residue is K-27 in mammals (Figure 1B, black arrow). The mouse and rat parkin homologues have been recently compared to Drosophila parkin [45], however a number of the above features were not discussed. Overall parkin appears to be highly conserved between mammalian and dipteran species suggesting conservation of function among these species.
###end p 20
###begin title 21
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 83 93 79 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
parkin suppresses degeneration of the ommaditial array in flies that express alpha-synuclein in the eye
###end title 21
###begin p 22
###xml 68 75 68 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 129 137 129 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In situ </italic>
###xml 171 178 171 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 203 214 203 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 246 253 246 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 298 307 298 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GMR-Gal4 </italic>
###xml 381 390 381 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 455 464 451 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein</italic>
###xml 483 485 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 486 488 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 517 527 509 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
###xml 534 545 526 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 595 597 587 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 641 650 629 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein</italic>
###xml 689 696 677 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 713 723 697 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
###xml 816 826 796 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
###xml 879 881 859 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 884 886 864 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 946 956 922 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
###xml 960 967 936 943 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 994 999 970 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B,2C</xref>
###xml 1082 1092 1054 1064 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
###xml 1130 1132 1102 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1206 1208 1178 1180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2D</xref>
###xml 1387 1397 1355 1365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
###xml 1401 1408 1369 1376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 1464 1469 1432 1437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2E,2F</xref>
###xml 1530 1537 1498 1505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 1554 1563 1518 1527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein</italic>
###xml 505 510 <span type="species:ncbi:9606">human</span>
###xml 701 706 <span type="species:ncbi:9606">human</span>
We generated stable transgenic flies that can conditionally express parkin when the UAS/Gal4 expression system is utilized [46]. In situ hybridization was used to confirm parkin expression in transgenic Drosophila (data not shown). Expression of parkin was directed to the developing eye using the GMR-Gal4 transgene resulting in no obvious alteration of the eye (data not shown). In vitro and cell culture research suggests that parkin can prevent alpha-synuclein-induced toxicity [31,47]. Expression of human alpha-synuclein in the Drosophila eye causes premature deterioration of the retina [32]. To examine if parkin could prevent alpha-synuclein-induced degeneration, we co-expressed parkin with human alpha-synuclein in the developing eye. Cross-sections of the retinas of one-day-old flies that express alpha-synuclein appear to be intact, as previously described (Figure 2A) [32]. The retinas of one-day-old flies that express both alpha-synuclein and parkin also appear normal (Figure 2B,2C). As previously described, the retinas of thirty-day-old flies that express alpha-synuclein show signs of premature degeneration [32]. Degeneration of the normal architecture of the eye is apparent (Figure 2D, black arrows) and reflects the disruption of the normal placement and alignment of the photoreceptors and supporting cells. In contrast, thirty-day-old flies that express alpha-synuclein and parkin maintain their ommatidial arrays and morphology (Figure 2E,2F). This observation demonstrates that directed expression of parkin suppresses alpha-synuclein-dependent degeneration of the ommatidial array.
###end p 22
###begin p 23
###xml 133 143 129 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
###xml 144 146 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 189 199 181 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
###xml 203 209 195 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin</italic>
###xml 313 323 301 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
###xml 461 471 445 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
###xml 479 481 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 486 488 470 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3D</xref>
###xml 521 531 501 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
###xml 535 542 515 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 550 558 530 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B,3C,3E</xref>
###xml 563 565 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3F</xref>
###xml 583 593 559 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
Retinal damage can be observed by examining an optical effect termed the pseudopupil, which is lost in aged flies that express alpha-synuclein [32]. We examined flies that co-express alpha-synuclein and parkin, and there appeared to be some retention of this optical effect compared with flies that express alpha-synuclein alone (data not shown). Scanning electron microscopy of eyes revealed no obvious deterioration of the surface in flies that express alpha-synuclein (Figure 3A and 3D) or flies that co-express alpha-synuclein and parkin (Figure 3B,3C,3E and 3F). Although alpha-synuclein causes degeneration of the ommatidial array, the external structure of the eye is unaffected.
###end p 23
###begin title 24
###xml 23 30 23 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
Directed-expression of parkin to dopaminergic neurons does not affect climbing ability
###end title 24
###begin p 25
###xml 22 33 22 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 252 254 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 262 269 262 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 429 431 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 461 468 461 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 525 527 525 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 561 568 561 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
Young wild-type adult Drosophila exhibit a strong negative geotaxis, which is increased by mechanical stimulation [48,49]. In order to measure climbing ability, flies are placed in a vial, gently tapped to the bottom and allowed to climb up the sides [32]. When parkin is expressed in the dopaminergic neurons, these flies do not show any change in their climbing ability over their life span when compared with controls (Figure 4A). In addition, expression of parkin in dopaminergic neurons does not alter life span (Figure 4B). These results demonstrate that parkin expression in the dopaminergic neurons has little effect upon climbing ability or life span.
###end p 25
###begin title 26
###xml 24 34 20 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
Parkin suppresses alpha-synuclein induced loss of climbing ability
###end title 26
###begin p 27
###xml 25 34 21 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein</italic>
###xml 107 116 103 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ddc-Gal4 </italic>
###xml 255 257 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 277 284 273 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 295 305 287 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
###xml 364 366 356 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 388 395 380 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 447 457 435 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
Flies that express alpha-synuclein, specifically in their dopaminergic neurons through the activity of the Ddc-Gal4 transgene, were assayed for their climbing ability over their life span, and were found to prematurely lose their climbing ability (Figure 5A). Co-expression of parkin with alpha-synuclein suppresses this premature loss of climbing ability (Figure 5A). This suggests that parkin can act to prevent the deleterious effects of alpha-synuclein expression.
###end p 27
###begin p 28
###xml 219 229 215 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
###xml 271 281 263 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
###xml 286 293 278 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 301 303 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
Aging assays were carried out in tandem with the climbing assays described above in order to account for changes in climbing ability as a result of premature senescence. Median survival age for flies that express alpha-synuclein is similar to flies that co-express alpha-synuclein with parkin (Figure 5B). This indicates that differences in climbing ability were not due to differences in life span.
###end p 28
###begin title 29
Discussion
###end title 29
###begin p 30
###xml 0 18 0 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila parkin </italic>
###xml 71 82 71 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A. gambiae </italic>
###xml 153 155 153 155 <underline xmlns:xlink="http://www.w3.org/1999/xlink">Ub</underline>
###xml 164 165 164 165 <underline xmlns:xlink="http://www.w3.org/1999/xlink">l</underline>
###xml 183 184 183 184 <underline xmlns:xlink="http://www.w3.org/1999/xlink">U</underline>
###xml 190 191 190 191 <underline xmlns:xlink="http://www.w3.org/1999/xlink">P</underline>
###xml 197 198 197 198 <underline xmlns:xlink="http://www.w3.org/1999/xlink">D</underline>
###xml 211 212 211 212 <underline xmlns:xlink="http://www.w3.org/1999/xlink">R</underline>
###xml 218 219 218 219 <underline xmlns:xlink="http://www.w3.org/1999/xlink">I</underline>
###xml 230 231 230 231 <underline xmlns:xlink="http://www.w3.org/1999/xlink">N</underline>
###xml 234 235 234 235 <underline xmlns:xlink="http://www.w3.org/1999/xlink">G</underline>
###xml 264 265 264 265 <underline xmlns:xlink="http://www.w3.org/1999/xlink">I</underline>
###xml 268 269 268 269 <underline xmlns:xlink="http://www.w3.org/1999/xlink">B</underline>
###xml 276 277 276 277 <underline xmlns:xlink="http://www.w3.org/1999/xlink">R</underline>
###xml 374 390 374 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D. melanogaster </italic>
###xml 394 404 394 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A. gambiae</italic>
###xml 725 727 725 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 968 969 968 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 972 974 972 974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 1253 1255 1253 1255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 1335 1336 1335 1336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 1339 1341 1339 1341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 1483 1485 1483 1485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 1668 1670 1668 1670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 1797 1799 1797 1799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1984 1991 1984 1991 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 2034 2036 2034 2036 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 2078 2085 2078 2085 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 2285 2296 2285 2296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 71 81 <span type="species:ncbi:7165">A. gambiae</span>
###xml 374 389 <span type="species:ncbi:7227">D. melanogaster</span>
###xml 394 404 <span type="species:ncbi:7165">A. gambiae</span>
###xml 627 635 <span type="species:ncbi:9606">Patients</span>
###xml 898 906 <span type="species:ncbi:9606">patients</span>
###xml 2337 2342 <span type="species:ncbi:9606">human</span>
Drosophila parkin has a high degree of similarity to the mammalian and A. gambiae homologues. The five characteristic domains of the parkin protein, the Ubiquitin- like Domain (UBL), Unique Parkin Domain (UPD), Really Interesting New Gene finger 1 (RING1) domain, In- Between Ring (IBR) domain and RING2 all show a high degree of similarity. In addition, the two dipterans, D. melanogaster and A. gambiae, have a highly conserved extra segment of 15 amino acids at the amino-terminal of the protein. The regions between the three carboxy-terminus domains are also highly conserved, which may indicate conservation of function. Patients with ARJP caused by mutations in the UBL domain exhibit signs of lost substrate binding [23]. The UBL domain also appears to be involved in binding the Rpn10 subunit of the 26S proteasome as the R42P amino acid substitution in this domain was identified in ARJP patients and results in impaired proteasome binding of parkin (Figure 6) [50]. Alterations of the RING1, RING2 and IBR domains of parkin result in an almost complete loss of ubiquitin conjugating enzyme H7 (UbcH7)-binding activity, which indicates that all three domains are functionally important in recruiting specific E2 ubiquitin conjugating enzymes [51]. The RING1 and RING2 domains are thought to collaborate to trap UbcH7 (Figure 6) [51]. Amino acid substitutions in the RING1 domain change the subcellular localization of parkin and enhance cytoplasmic and nuclear inclusions [52]. In addition, the amino acid substitutions C289G and C418R, which replace conserved cysteine residues in the RING domains, significantly decrease the solubility of parkin in cells [53]. Ubiquitination generally occurs near the amino-terminus of proteins and ubiquitin monomers are attached to lysine residues [25]. Several lysine residues are absolutely conserved, including one in the UBL and two in the UPD, and these may be targets for ubiquitination. The existence of orthologues of mammalian parkin in invertebrates but not plants nor fungi [54] suggest an animal specific function for parkin activity. The highly conserved protein domains and sub-domains suggest the probable conservation of each domain's function, and given the high degree of similarity we suggest that the function of the Drosophila parkin protein is similar to that of the human parkin protein.
###end p 30
###begin p 31
###xml 47 54 47 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 177 184 177 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 335 337 335 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
We demonstrate that the directed expression of parkin in the dopaminergic neurons and developing eyes leads to no obvious adverse effects. The unaltered phenotype observed when parkin is expressed in dopaminergic neurons is likely due to substrate specificity and to the ability of the parkin protein to target itself for degradation [28]. Under conditions of over-expression, parkin does not seem to target and tag essential proteins for degradation promiscuously. This may represent an excellent fail-safe mechanism the cell has developed to balance the levels of both parkin and its substrates.
###end p 31
###begin p 32
###xml 4 15 4 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 103 105 103 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 149 151 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 152 154 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 170 177 170 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 194 204 190 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
###xml 239 248 231 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein</italic>
###xml 388 396 376 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 404 405 392 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 540 542 524 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 602 604 582 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 646 655 622 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein</italic>
###xml 719 729 691 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
###xml 744 754 716 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
###xml 894 895 862 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
The Drosophila model of ADPD has been used to examine the effect of various pharmacological agents [34,36] and other genetic aspects of the disease [35,37]. We expressed parkin along with alpha-synuclein and found the suppression of alpha-synuclein-induced retinal degeneration and premature loss of climbing. These results indicate that parkin may target alpha-synuclein for degradation in vivo (Figure 6). Although coimmuno-precipitation studies have shown that parkin does not interact with or ubiquitinate non-modified alpha-synuclein [29], parkin will ubiquitinate O-glycosylated alpha-synuclein [26]. Since we show suppression of the alpha-synuclein-induced phenotype, we believe that ectopically expressed alpha-synuclein is modified in Drosophila, enabling its ubiquitination by parkin. The modification of alpha-synuclein and subsequent ubiquitination by parkin is presented in Figure 6.
###end p 32
###begin p 33
###xml 298 305 298 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 370 379 366 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein</italic>
###xml 403 413 399 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
###xml 493 500 489 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 452 458 <span type="species:ncbi:9606">humans</span>
In order to select rational potential therapeutic agents, the molecular mechanisms behind disease progression must be characterized. Gene function studies with homologues of disease-causing genes in model organisms have been made practical through the advent of genome projects. Over-expression of parkin has no apparent adverse consequences and it suppresses the alpha-synuclein-induced PD symptoms in Drosophila. If this relationship is conserved in humans, we suggest that up-regulation of parkin should be a viable treatment for PD, and the selection of therapeutic strategies should be directed towards this end.
###end p 33
###begin title 34
Conclusions
###end title 34
###begin p 35
###xml 64 71 64 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 122 131 118 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein</italic>
###xml 140 151 136 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 534 541 526 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
Our experiments demonstrate that the directed expression of the parkin gene counteracts the PD-like symptoms in the alpha-synuclein-induced Drosophila model of PD. Manipulation of the ubiquitin/proteasome degradation pathway in such a specific manner apparently remedies the toxic accumulation of alpha-synuclein. This study demonstrates the success of selective targeting of toxic proteins for degradation as an approach to address neurodegenerative conditions such as Parkinson's disease. The development of therapies that regulate parkin expression or parkin protein activity may be crucial in the treatment of PD.
###end p 35
###begin title 36
Methods
###end title 36
###begin title 37
Bioinformatic and sequence analysis
###end title 37
###begin p 38
###xml 4 28 4 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila melanogaster </italic>
###xml 41 48 41 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 205 223 205 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila parkin </italic>
###xml 275 277 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 486 493 486 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 537 539 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 722 736 722 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R. norvegicus </italic>
###xml 751 763 751 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M. musculus </italic>
###xml 780 791 780 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A. gambiae </italic>
###xml 836 852 836 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D. melanogaster </italic>
###xml 877 879 877 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 937 952 937 952 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D. melanogaster</italic>
###xml 954 964 954 964 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A. gambiae</italic>
###xml 966 979 966 979 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R. norvegicus</italic>
###xml 981 993 981 993 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M. musculus </italic>
###xml 997 1008 997 1008 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H. sapiens </italic>
###xml 1126 1128 1126 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 1129 1131 1129 1131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 4 27 <span type="species:ncbi:7227">Drosophila melanogaster</span>
###xml 144 149 <span type="species:ncbi:9606">human</span>
###xml 722 735 <span type="species:ncbi:10116">R. norvegicus</span>
###xml 751 762 <span type="species:ncbi:10090">M. musculus</span>
###xml 780 790 <span type="species:ncbi:7165">A. gambiae</span>
###xml 836 851 <span type="species:ncbi:7227">D. melanogaster</span>
###xml 937 952 <span type="species:ncbi:7227">D. melanogaster</span>
###xml 954 964 <span type="species:ncbi:7165">A. gambiae</span>
###xml 966 979 <span type="species:ncbi:10116">R. norvegicus</span>
###xml 981 992 <span type="species:ncbi:10090">M. musculus</span>
###xml 997 1007 <span type="species:ncbi:9606">H. sapiens</span>
The Drosophila melanogaster homologue of parkin was identified through a search of the Berkeley Drosophila Genome Project [55] queried with the human parkin amino acid sequence, AB009973.1. A clone of the Drosophila parkin cDNA (SD01679) was obtained from Research Genetics [56], sub-cloned and sequenced (Cortec DNA Service Laboratories Inc., Kingston, ON, Canada). The intron/exon map was constructed by comparison of the cDNA to the corresponding genomic region. Other homologues of parkin were identified with the tblastn algorithm [57] of the National Center for Biotechnology Information (NCBI) using the theoretical translation of SD01679 cDNA. The blast2 sequence comparison program (NCBI) was used to compare the R. norvegicus (NM_020093.1), M. musculus (AB019558.1) and A. gambiae (XM316606.1) sequences individually with the D. melanogaster parkin protein sequence [57]. The multi-alignment of the five parkin homologues from D. melanogaster, A. gambiae, R. norvegicus, M. musculus and H. sapiens was constructed by editing the results from the multialign ClustalW program from the Pole Bio-Informatique Lyonnaise [58,59].
###end p 38
###begin title 39
Fly stocks and culture
###end title 39
###begin p 40
###xml 100 120 100 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS-&#945;-synuclein </italic>
###xml 121 123 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 129 137 125 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ddc-Gal4</italic>
###xml 137 142 133 138 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4.36 </sup>
###xml 149 151 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 171 180 167 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GMR-Gal4 </italic>
###xml 187 189 183 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 275 278 271 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bgl</italic>
###xml 281 284 277 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xho</italic>
###xml 310 317 306 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 355 361 351 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pUAST </italic>
###xml 384 395 380 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS-parkin </italic>
###xml 540 541 535 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 541 546 536 541 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1118 </sup>
###xml 584 603 579 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS-&#945;-synuclein</italic>
###xml 604 614 595 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS-parkin</italic>
###xml 614 618 605 609 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1.1 </sup>
###xml 622 641 613 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS-&#945;-synuclein</italic>
###xml 642 652 629 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS-parkin</italic>
###xml 652 656 639 643 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2.1 </sup>
###xml 737 746 724 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ddc-Gal4 </italic>
###xml 794 803 781 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GMR-Gal4 </italic>
###xml 866 867 853 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 867 872 854 859 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1118 </sup>
###xml 891 911 878 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS-&#945;-synuclein </italic>
###xml 927 937 910 920 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS-parkin</italic>
###xml 937 941 920 924 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1.1 </sup>
###xml 944 954 927 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS-parkin</italic>
###xml 954 957 937 940 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2.1</sup>
###xml 1004 1009 <span type="species:ncbi:4932">yeast</span>
Dr. M. Feany (Harvard Medical School) and Dr. J. Hirsh (University of Virginia) generously provided UAS-alpha-synuclein [32] and Ddc-Gal44.36 flies [60] respectively. The GMR-Gal4 flies [61] were obtained from the Bloomington Drosophila Stock Center at Indiana University. A BglII/XhoI fragment containing the parkin cDNA (SD01679) was subcloned into the pUAST vector to generate the UAS-parkin transgene. Two independent transgenic lines were generated using heat shock pi as a source of transposase and standard injection techniques into w1118 embryos. Double transgenic lines with UAS-alpha-synuclein;UAS-parkin1.1 and UAS-alpha-synuclein;UAS-parkin2.1 were generated using standard techniques. To drive expression of the transgenes, Ddc-Gal4 (for expression in the dopaminergic neurons) or GMR-Gal4 (for expression in the eye) homozygous females were crossed to w1118 males (control) or UAS-alpha-synuclein with or without UAS-parkin1.1 or UAS-parkin2.1. All flies were cultured on standard cornmeal/yeast/molasses/agar media at 25degreesC.
###end p 40
###begin title 41
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In situ </italic>
In situ hybridization analysis
###end title 41
###begin p 42
###xml 164 171 164 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 239 246 239 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 374 381 374 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 698 699 698 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 699 703 699 703 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1118</sup>
###xml 708 709 708 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 709 713 709 713 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1118</sup>
###xml 715 737 715 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GMR-Gal4/+; UAS-parkin</italic>
###xml 737 740 737 740 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1.1</sup>
###xml 751 752 751 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 752 756 752 756 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1118</sup>
###xml 758 768 758 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GMR-Gal4/+</italic>
###xml 770 780 770 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS-parkin</italic>
###xml 780 783 780 783 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2.1</sup>
Third instar larvae were dissected in PBS, fixed in 4% formaldehyde and dehydrated in methanol and ethanol. The carcases were probed with a DIG labelled anti-sense parkin RNA probe generated from a linear cut plasmid containing the entire parkin cDNA using the Roche Applied Science DIG Northern starter kit and reduced in size with carbonate buffer treatment. To visualize parkin RNA alkaline phosphatase labelled anti-DIG anti-bodies were incubated with the carcases and subjected to alkaline phosphate treatment as per the Roche Applied Science DIG application manual. The eye discs were dissected out completely and examined under light microscopy. The genotypes of the larvae examined were 1) w1118; 2) w1118; GMR-Gal4/+; UAS-parkin1.1/+; and 3) w1118; GMR-Gal4/+; UAS-parkin2.1/+ and at least ten of each genotype were examined.
###end p 42
###begin title 43
Aging analysis
###end title 43
###begin p 44
###xml 332 334 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 385 388 379 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS</italic>
###xml 395 404 385 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein</italic>
###xml 408 416 398 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ddc-Gal4</italic>
###xml 426 429 416 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS</italic>
###xml 436 445 422 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein</italic>
###xml 449 459 435 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS-parkin</italic>
###xml 459 462 445 448 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2.1</sup>
###xml 463 472 449 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ddc-Gal4 </italic>
###xml 479 482 465 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS</italic>
###xml 489 498 471 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein</italic>
###xml 502 512 484 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS-parkin</italic>
###xml 512 515 494 497 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1.1</sup>
###xml 516 525 498 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ddc-Gal4 </italic>
###xml 532 533 514 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 533 537 515 519 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1118</sup>
###xml 539 550 521 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ddc-Gal4/+ </italic>
###xml 557 567 539 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS-parkin</italic>
###xml 567 570 549 552 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1.1</sup>
###xml 571 580 553 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ddc-Gal4 </italic>
###xml 591 601 573 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS-parkin</italic>
###xml 601 604 583 586 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2.1</sup>
###xml 605 614 587 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ddc-Gal4 </italic>
###xml 139 144 <span type="species:ncbi:4932">yeast</span>
Adult males were collected under gaseous carbon dioxide anaesthetic and aged in small groups (~10 or less per vial) upon standard cornmeal/yeast/molasses/agar media at 25degreesC in upright standard plastic shell vials. The flies were scored for viability every two to three days and transferred to fresh media without anaesthesia [62]. The numbers of individuals aged are as follows: UAS-alpha-synuclein/+; Ddc-Gal4/+ = 191; UAS-alpha-synuclein/+; UAS-parkin2.1/Ddc-Gal4 = 292; UAS-alpha-synuclein/+; UAS-parkin1.1/Ddc-Gal4 = 204; w1118; Ddc-Gal4/+ = 173; UAS-parkin1.1/Ddc-Gal4 = 262; and UAS-parkin2.1/Ddc-Gal4 = 227.
###end p 44
###begin title 45
Locomotion assay
###end title 45
###begin p 46
###xml 80 82 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
Flies were assayed for their ability to climb as described by Feany and Bender [32]. Every five days, forty male flies from a cohort of flies were assayed for their ability to climb six centimetres in eighteen seconds in a sterile plastic vial. Twenty trials were carried out for each time point. Data shown represent the results from flies tested over ninety days.
###end p 46
###begin title 47
###xml 36 47 36 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
Scanning electron microscopy of the Drosophila eye
###end title 47
###begin p 48
###xml 32 33 32 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 33 37 33 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1118</sup>
###xml 39 42 39 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS</italic>
###xml 49 67 45 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein/GMR-Gal4</italic>
###xml 72 73 68 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 73 77 69 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1118</sup>
###xml 79 82 75 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS</italic>
###xml 89 107 81 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein/GMR-Gal4</italic>
###xml 109 119 101 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS-parkin</italic>
###xml 119 122 111 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1.1</sup>
###xml 133 134 125 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 134 138 126 130 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1118</sup>
###xml 140 143 132 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS</italic>
###xml 150 168 138 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein/GMR-Gal4</italic>
###xml 170 180 158 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS-parkin</italic>
###xml 180 183 168 171 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2.1</sup>
Flies were of each genotype [1) w1118; UAS-alpha-synuclein/GMR-Gal4; 2) w1118; UAS-alpha-synuclein/GMR-Gal4; UAS-parkin1.1/+; and 3) w1118; UAS-alpha-synuclein/GMR-Gal4; UAS-parkin2.1/+] aged and frozen in a -70degreesC ethanol bath. Whole flies were mounted, desiccated overnight and coated in gold before photography at 150 times magnification with a Hitachi S-570 SEM as per standard methods. For each condition at least six flies were analysed.
###end p 48
###begin title 49
###xml 28 39 28 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
Histological examination of Drosophila adult retinas
###end title 49
###begin p 50
###xml 16 17 16 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 17 21 17 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1118</sup>
###xml 23 26 23 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS</italic>
###xml 33 51 29 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein/GMR-Gal4</italic>
###xml 56 57 52 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 57 61 53 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1118</sup>
###xml 63 66 59 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS</italic>
###xml 73 91 65 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein/GMR-Gal4</italic>
###xml 93 103 85 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS-parkin</italic>
###xml 103 106 95 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1.1</sup>
###xml 117 118 109 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 118 122 110 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1118</sup>
###xml 124 127 116 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS</italic>
###xml 134 152 122 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein/GMR-Gal4</italic>
###xml 154 164 142 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS-parkin</italic>
###xml 164 167 152 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2.1</sup>
Adult flies [1) w1118; UAS-alpha-synuclein/GMR-Gal4; 2) w1118; UAS-alpha-synuclein/GMR-Gal4; UAS-parkin1.1/+; and 3) w1118; UAS-alpha-synuclein/GMR-Gal4; UAS-parkin2.1/+] were aged (one or thirty days after eclosion), fixed in Karnovsky's fixative and embedded in epon. Tangential retinal sections were prepared at a thickness of 0.5 mum and stained with toluidine blue, examined by light microscopy and photographed at magnification of 800 times.
###end p 50
###begin title 51
Authors' contributions
###end title 51
###begin p 52
###xml 333 344 333 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
AFMH conducted the molecular and bioinformatic analyses, genetic manipulation, transgenic generation, sample preparation, light microscopy, scanning electron microscopy, aging bioassays and behavioural experiments as well as designing the experiments and drafting the manuscript. BES initiated the bioinformatic investigation of the Drosophila parkin gene, collaborated with experimental design, participated in the creation of transgenics, edited the manuscript, as well as acting as supervisor and primary investigator.
###end p 52
###begin title 53
Acknowledgements
###end title 53
###begin p 54
###xml 837 845 837 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
This research was funded by the Natural Sciences and Engineering Research Council of Canada and the Dean of Science of Memorial University of Newfoundland (start-up funds) to BES. AFMH was partially funded by a Graduate Student Demonstratorship. We thank E. Lloyd Smith and Bernard Healy (Faculty of Engineering, Memorial University of Newfoundland) for design and production of the climbing assay device. We thank Lisa Lee and Roy Ficken (Department of Biology, Memorial University of Newfoundland) for help with SEM and photography respectively, and Kate Williams and Howard Gladney (Faculty of Medicine, Memorial University of Newfoundland) for help with sectioning. We thank John P. Phillips (Department of Molecular Biology and Genetics, University of Guelph) for advice on matters of longevity. We thank Jamie Kramer for advice on in situ hybridization and Peter Earle for help with citation software. We also thank Dr. Helene Volkoff, Dr. H. Dawn Marshall, Lisa Saunders and Justin Moores for comments on the manuscript.
###end p 54
###begin article-title 55
An essay on the Shaking Palsy
###end article-title 55
###begin article-title 56
The genetics of Parkinson's disease
###end article-title 56
###begin article-title 57
New Animal Models for Parkinson's Disease
###end article-title 57
###begin article-title 58
Parkin and the molecular pathways of Parkinson's disease
###end article-title 58
###begin article-title 59
Genetics of Parkinson's disease and biochemical studies of implicated gene products
###end article-title 59
###begin article-title 60
The genetics of Parkinson's disease
###end article-title 60
###begin article-title 61
Parkin and Parkinson's disease
###end article-title 61
###begin article-title 62
Mapping of a gene for Parkinson's disease to chromosome 4q21-q23
###end article-title 62
###begin article-title 63
Mutation in the alpha-Synuclein Gene Identified in Families with Parkinson's Disease
###end article-title 63
###begin article-title 64
###xml 47 52 <span type="species:ncbi:9606">human</span>
Identification of two distinct synucleins from human brain
###end article-title 64
###begin article-title 65
The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease
###end article-title 65
###begin article-title 66
A role for alpha-synuclein in the regulation of dopamine biosynthesis
###end article-title 66
###begin article-title 67
###xml 89 94 <span type="species:ncbi:9606">human</span>
Co-ordinate transcriptional regulation of dopamine synthesis genes by alpha-synuclein in human neuroblastoma cell lines
###end article-title 67
###begin article-title 68
Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
###end article-title 68
###begin article-title 69
Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.
###end article-title 69
###begin article-title 70
Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy
###end article-title 70
###begin article-title 71
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
###end article-title 71
###begin article-title 72
Autosomal-recessive juvenile parkinsonism in a Jewish Yemenite kindred: mutation of Parkin gene
###end article-title 72
###begin article-title 73
###xml 39 46 <span type="species:ncbi:9606">patient</span>
A new mutation in the parkin gene in a patient with atypical autosomal recessive juvenile parkinsonism
###end article-title 73
###begin article-title 74
###xml 24 32 <span type="species:ncbi:9606">patients</span>
Clinical analysis of 17 patients in 12 Japanese families with autosomal-recessive type juvenile parkinsonism.
###end article-title 74
###begin article-title 75
Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q
###end article-title 75
###begin article-title 76
An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene
###end article-title 76
###begin article-title 77
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase.
###end article-title 77
###begin article-title 78
The Ubiquitin System
###end article-title 78
###begin article-title 79
Mechanisms underlying ubiquitination
###end article-title 79
###begin article-title 80
###xml 63 68 <span type="species:ncbi:9606">human</span>
Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease
###end article-title 80
###begin article-title 81
An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin
###end article-title 81
###begin article-title 82
Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1
###end article-title 82
###begin article-title 83
Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin- 1: implications for Lewy-body formation in Parkinson disease
###end article-title 83
###begin article-title 84
Parkin Suppresses Unfolded Protein Stress-induced Cell Death through Its E3 Ubiquitin-protein Ligase Activity.
###end article-title 84
###begin article-title 85
Parkin protects against the toxicity associated with mutant alpha- synuclein: proteasome dysfunction selectively affects catecholaminergic neurons
###end article-title 85
###begin article-title 86
A Drosophila model of Parkinson's disease
###end article-title 86
###begin article-title 87
Gene expression changes presage neurodegeneration in a Drosophila model of Parkinson's disease
###end article-title 87
###begin article-title 88
###xml 84 107 <span type="species:ncbi:7227">Drosophila melanogaster</span>
Effects of pharmacological agents upon a transgenic model of Parkinson's disease in Drosophila melanogaster
###end article-title 88
###begin article-title 89
Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease
###end article-title 89
###begin article-title 90
Pharmacological prevention of Parkinson disease in Drosophila
###end article-title 90
###begin article-title 91
Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila
###end article-title 91
###begin article-title 92
Comparison of the consensus sequence flanking translational start sites in Drosophila and vertebrates
###end article-title 92
###begin article-title 93
Codon usage bias and tRNA abundance in Drosophila
###end article-title 93
###begin article-title 94
Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants
###end article-title 94
###begin article-title 95
###xml 44 61 <span type="species:ncbi:7165">Anopheles gambiae</span>
The genome sequence of the malaria mosquito Anopheles gambiae
###end article-title 95
###begin article-title 96
Does failure of parkin-mediated ubiquitination cause juvenile parkinsonism?
###end article-title 96
###begin article-title 97
RING for destruction?
###end article-title 97
###begin article-title 98
A novel transactivation domain in parkin
###end article-title 98
###begin article-title 99
###xml 49 72 <span type="species:ncbi:7227">Drosophila melanogaster</span>
Genomic organization and expression of parkin in Drosophila melanogaster
###end article-title 99
###begin article-title 100
Targeted gene expression as a means of altering cell fates and generating dominant phenotypes.
###end article-title 100
###begin article-title 101
Parkin suppresses wild-type alpha-synuclein-induced toxicity in SHSY-5Y cells
###end article-title 101
###begin article-title 102
###xml 26 49 <span type="species:ncbi:7227">Drosophila melanogaster</span>
Hypergravity and aging in Drosophila melanogaster. 4. Climbing activity
###end article-title 102
###begin article-title 103
###xml 72 95 <span type="species:ncbi:7227">Drosophila melanogaster</span>
Effects of temperature on the life span, vitality and fine structure of Drosophila melanogaster
###end article-title 103
###begin article-title 104
Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin-like domain
###end article-title 104
###begin article-title 105
Parkin is linked to the ubiquitin pathway
###end article-title 105
###begin article-title 106
RING finger 1 mutations in Parkin produce altered localization of the protein
###end article-title 106
###begin article-title 107
###xml 68 73 <span type="species:ncbi:9606">human</span>
The C289G and C418R missense mutations cause rapid sequestration of human Parkin into insoluble aggregates
###end article-title 107
###begin article-title 108
Comparative genomics of the RBR family, including the Parkinson's disease-related gene parkin and the genes of the ariadne subfamily
###end article-title 108
###begin article-title 109
http://www.fruitfly.org/blast
###end article-title 109
###begin article-title 110
A Drosophila full-length cDNA resource
###end article-title 110
###begin article-title 111
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs
###end article-title 111
###begin article-title 112
http://pbil.univ-lyon1.fr/
###end article-title 112
###begin article-title 113
CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.
###end article-title 113
###begin article-title 114
###xml 95 118 <span type="species:ncbi:7227">Drosophila melanogaster</span>
Ectopic G-protein expression in dopamine and serotonin neurons blocks cocaine sensitization in Drosophila melanogaster.
###end article-title 114
###begin article-title 115
Reiterative use of the EGF receptor triggers differentiation of all cell types in the Drosophila eye
###end article-title 115
###begin article-title 116
###xml 78 101 <span type="species:ncbi:7227">Drosophila melanogaster</span>
Phenotypic consequences of copper-zinc superoxide dismutase overexpression in Drosophila melanogaster
###end article-title 116
###begin title 117
Figures and Tables
###end title 117
###begin p 118
###xml 0 57 0 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Dipteran and mammalian parkin proteins are well conserved</bold>
###xml 95 119 95 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila melanogaster </italic>
###xml 236 260 236 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila melanogaster </italic>
###xml 288 305 288 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Anopheles gambiae</italic>
###xml 307 324 307 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rattus norvegicus</italic>
###xml 326 339 326 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mus musculus </italic>
###xml 343 355 343 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Homo sapiens</italic>
###xml 95 118 <span type="species:ncbi:7227">Drosophila melanogaster</span>
###xml 236 259 <span type="species:ncbi:7227">Drosophila melanogaster</span>
###xml 288 305 <span type="species:ncbi:7165">Anopheles gambiae</span>
###xml 307 324 <span type="species:ncbi:10116">Rattus norvegicus</span>
###xml 326 338 <span type="species:ncbi:10090">Mus musculus</span>
###xml 343 355 <span type="species:ncbi:9606">Homo sapiens</span>
Dipteran and mammalian parkin proteins are well conserved. (A) Schematic representation of the Drosophila melanogaster parkin transcription unit and its location in the genomic scaffolding region AE003593. (B) ClustalW alignment of the Drosophila melanogaster parkin with homologues from Anopheles gambiae, Rattus norvegicus, Mus musculus and Homo sapiens. Highlighted are the Ubiquitin-like Domain (UBL) (green box); the Unique Parkin Domain (UPD) (red box); RING1 and RING2 (blue boxes); In-Between Ring Domain (IRB) (black box). "*" and red lettering indicates amino acids that are identical in all sequences in the alignment. ":" and green lettering indicates conserved substitutions. "." and blue lettering indicates semi-conserved substitutions.
###end p 118
###begin p 119
###xml 14 21 14 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 38 47 34 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein</italic>
###xml 0 76 0 72 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Expression of <italic>parkin </italic>suppresses &#945;-<italic>synuclein</italic>-induced retinal degeneration</bold>
###xml 103 113 95 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
###xml 130 137 122 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 504 505 495 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 505 509 496 500 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1118</sup>
###xml 511 514 502 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS</italic>
###xml 521 539 508 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein/GMR-Gal4</italic>
###xml 547 548 534 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 548 552 535 539 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1118</sup>
###xml 554 557 541 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS</italic>
###xml 563 582 546 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-synuclein/GMR-Gal4</italic>
###xml 584 594 567 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS-parkin</italic>
###xml 594 597 577 580 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1.1</sup>
###xml 611 612 594 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 612 616 595 599 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1118</sup>
###xml 618 621 601 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS</italic>
###xml 628 646 607 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein/GMR-Gal4</italic>
###xml 648 658 627 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS-parkin</italic>
###xml 658 661 637 640 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2.1</sup>
Expression of parkin suppresses alpha-synuclein-induced retinal degeneration. Flies that express alpha-synuclein with and without parkin were aged to 1 or 30 days old. They were fixed and embedded in epon. Tangential sections (0.5 mum thick) of the retina were cut, stained with toludine blue and examined by light microscopy. Panels A-C represent one-day-old flies and panels D-F represent thirty-day-old flies. Black arrows indicate degeneration of the ommatidial architecture. The genotypes are (A,D) w1118; UAS-alpha-synuclein/GMR-Gal4, (B,E) w1118; UAS-alpha-synuclein/GMR-Gal4; UAS-parkin1.1/+, and (C,F) w1118; UAS-alpha-synuclein/GMR-Gal4; UAS-parkin2.1/+. Scale bar is 15 mum.
###end p 119
###begin p 120
###xml 20 30 16 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
###xml 47 54 43 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 0 104 0 100 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Expression of &#945;-<italic>synuclein </italic>with and without <italic>parkin </italic>does not affect the external morphology of the eye</bold>
###xml 163 173 155 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
###xml 190 197 182 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 370 371 362 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 371 375 363 367 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1118</sup>
###xml 377 380 369 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS</italic>
###xml 387 405 375 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein/GMR-Gal4</italic>
###xml 413 414 401 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 414 418 402 406 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1118</sup>
###xml 420 423 408 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS</italic>
###xml 430 448 414 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein/GMR-Gal4</italic>
###xml 450 460 434 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS-parkin</italic>
###xml 460 463 444 447 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1.1</sup>
###xml 477 478 461 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 478 482 462 466 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1118</sup>
###xml 484 487 468 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS</italic>
###xml 494 512 474 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein/GMR-Gal4</italic>
###xml 514 524 494 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS-parkin</italic>
###xml 524 527 504 507 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2.1</sup>
Expression of alpha-synuclein with and without parkin does not affect the external morphology of the eye. Scanning electron microscopy of flies that express alpha-synuclein with and without parkin shows no change in their external morphology over thirty days. Panels A-C represent one-day-old flies and panels D-F represent thirty-day-old flies. The genotypes are (A,D) w1118; UAS-alpha-synuclein/GMR-Gal4, (B,E) w1118; UAS-alpha-synuclein/GMR-Gal4; UAS-parkin1.1/+, and (C,F) w1118; UAS-alpha-synuclein/GMR-Gal4; UAS-parkin2.1/+. Scale bar indicates 200 mum.
###end p 120
###begin p 121
###xml 14 21 14 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 0 66 0 66 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Expression of <italic>parkin </italic>does not affect climbing ability or life span</bold>
###xml 117 124 117 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 174 175 174 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 175 179 175 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1118</sup>
###xml 181 191 181 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS-parkin</italic>
###xml 191 194 191 194 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1.1</sup>
###xml 195 204 195 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ddc-Gal4 </italic>
###xml 227 228 227 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 228 232 228 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1118</sup>
###xml 234 244 234 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS-parkin</italic>
###xml 244 247 244 247 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2.1</sup>
###xml 248 257 248 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ddc-Gal4 </italic>
###xml 282 283 282 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 283 287 283 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1118</sup>
###xml 289 300 289 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ddc-Gal4/+ </italic>
###xml 508 515 508 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
Expression of parkin does not affect climbing ability or life span. Panel A - Climbing ability of flies that express parkin does not differ from control flies. Genotypes are w1118; UAS-parkin1.1/Ddc-Gal4 (green open triangle), w1118; UAS-parkin2.1/Ddc-Gal4 (orange open square) and w1118; Ddc-Gal4/+ (black open circles). The error bars show the standard error of the mean of twenty trials at each point. Please note that the error bars are mostly within the symbols. B - The life span of flies that express parkin does not differ from the control. The genotypes are marked the same as in panel A. The mortality of flies was examined every two days.
###end p 121
###begin p 122
###xml 14 21 14 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 38 47 34 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein</italic>
###xml 0 80 0 76 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Expression of <italic>parkin </italic>suppresses &#945;-<italic>synuclein</italic>-induced loss of climbing ability</bold>
###xml 116 123 112 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 133 143 125 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
###xml 200 210 188 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
###xml 304 305 292 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 305 309 293 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1118</sup>
###xml 311 314 299 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS</italic>
###xml 321 332 305 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein/+</italic>
###xml 334 345 318 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ddc-Gal4/+ </italic>
###xml 366 367 350 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 367 371 351 355 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1118</sup>
###xml 373 376 357 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS</italic>
###xml 383 394 363 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein/+</italic>
###xml 396 406 376 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS-parkin</italic>
###xml 406 409 386 389 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1.1</sup>
###xml 410 419 390 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ddc-Gal4 </italic>
###xml 440 441 420 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 441 445 421 425 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1118</sup>
###xml 447 450 427 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS</italic>
###xml 457 468 433 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein/+</italic>
###xml 470 480 446 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UAS-parkin</italic>
###xml 480 483 456 459 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2.1</sup>
###xml 484 493 460 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ddc-Gal4 </italic>
###xml 719 729 691 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">synuclein </italic>
###xml 746 753 718 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
Expression of parkin suppresses alpha-synuclein-induced loss of climbing ability. Panel A - Aged flies that express parkin and alpha-synuclein climb significantly better than flies that express alpha-synuclein (P < 0.001, one-way analysis of variance with supplementary Newman-Keuls test). Genotypes are w1118; UAS-alpha-synuclein/+; Ddc-Gal4/+ (green open square), w1118; UAS-alpha-synuclein/+; UAS-parkin1.1/Ddc-Gal4 (red open triangle), w1118; UAS-alpha-synuclein/+; UAS-parkin2.1/Ddc-Gal4 (blue upside down open triangle). The error bars show the standard error of the mean of twenty trials at each point. Please note that the error bars are mostly within the symbols. B - The life span of flies that express alpha-synuclein with and without parkin does not differ. The genotypes are marked the same as in panel A.
###end p 122
###begin p 123
###xml 0 58 0 54 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Model of parkin directed ubiquitination of &#945;-synuclein</bold>
###xml 550 552 538 540 <underline xmlns:xlink="http://www.w3.org/1999/xlink">Ub</underline>
###xml 560 561 548 549 <underline xmlns:xlink="http://www.w3.org/1999/xlink">l</underline>
###xml 579 580 567 568 <underline xmlns:xlink="http://www.w3.org/1999/xlink">U</underline>
###xml 586 587 574 575 <underline xmlns:xlink="http://www.w3.org/1999/xlink">P</underline>
###xml 593 594 581 582 <underline xmlns:xlink="http://www.w3.org/1999/xlink">D</underline>
###xml 614 615 602 603 <underline xmlns:xlink="http://www.w3.org/1999/xlink">R</underline>
###xml 621 622 609 610 <underline xmlns:xlink="http://www.w3.org/1999/xlink">I</underline>
###xml 633 634 621 622 <underline xmlns:xlink="http://www.w3.org/1999/xlink">N</underline>
###xml 637 638 625 626 <underline xmlns:xlink="http://www.w3.org/1999/xlink">G</underline>
###xml 670 671 658 659 <underline xmlns:xlink="http://www.w3.org/1999/xlink">I</underline>
###xml 673 674 661 662 <underline xmlns:xlink="http://www.w3.org/1999/xlink">B</underline>
###xml 681 682 669 670 <underline xmlns:xlink="http://www.w3.org/1999/xlink">R</underline>
Model of parkin directed ubiquitination of alpha-synuclein. The parkin protein consists of two functionally distinct regions. The UBL/UPD region binds target proteins such as glycosylated alpha-synuclein. The RING-box (RING1-IBR-RING2) region recruits specific E2 ubiquitin conjugating enzymes, which add ubiquitin monomers to the target protein. In addition to substrate binding the UBL domain interacts with the proteasome. Ubiquitin tagged alpha-synuclein is directed to the proteasome and degraded into polypeptides and ubiquitin monomers. UBL - Ubiquitin-like Domain, UPD - Unique Parkin Domain, RING1 or 2 - Really Interesting New Gene finger 1 or 2 domain, IBR - In-Between Ring domain.
###end p 123

